Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Backgrounds: The relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) o...

Full description

Bibliographic Details
Main Authors: Han Gyul Yoon, Dongryul Oh, Yong Chan Ahn, Jae Myoung Noh, Hongryull Pyo, Won Kyung Cho, Yun Mi Song, Minsu Park, Na Young Hwang, Jong-Mu Sun, Hong Kwan Kim, Jae Ill Zo, Young Mog Shim
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/4/925
id doaj-490f53dd6d7d440dbfb70cbefc7071fb
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Han Gyul Yoon
Dongryul Oh
Yong Chan Ahn
Jae Myoung Noh
Hongryull Pyo
Won Kyung Cho
Yun Mi Song
Minsu Park
Na Young Hwang
Jong-Mu Sun
Hong Kwan Kim
Jae Ill Zo
Young Mog Shim
spellingShingle Han Gyul Yoon
Dongryul Oh
Yong Chan Ahn
Jae Myoung Noh
Hongryull Pyo
Won Kyung Cho
Yun Mi Song
Minsu Park
Na Young Hwang
Jong-Mu Sun
Hong Kwan Kim
Jae Ill Zo
Young Mog Shim
Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Cancers
esophageal cancer
neoadjuvant chemoradiotherapy
sarcopenia
skeletal muscle loss
nutrition
inflammation
author_facet Han Gyul Yoon
Dongryul Oh
Yong Chan Ahn
Jae Myoung Noh
Hongryull Pyo
Won Kyung Cho
Yun Mi Song
Minsu Park
Na Young Hwang
Jong-Mu Sun
Hong Kwan Kim
Jae Ill Zo
Young Mog Shim
author_sort Han Gyul Yoon
title Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_short Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_full Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_fullStr Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_full_unstemmed Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_sort prognostic impact of sarcopenia and skeletal muscle loss during neoadjuvant chemoradiotherapy in esophageal cancer
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2020-04-01
description Backgrounds: The relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) of esophageal cancer patients. Methods: We retrospectively collected the medical records of 248 male patients diagnosed with squamous cell esophageal cancer and who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgery. We measured the cross-sectional area of the skeletal muscle at the L3 vertebra level using computed tomography images and calculated the skeletal muscle index (SMI). Sarcopenia was defined as SMI <52.4 cm<sup>2</sup>/m<sup>2</sup>, and excessive muscle loss was defined as SMI change <−10.0%/50 days during NACRT. Moreover, laboratory test results, such as albumin, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) before and after NACRT, were collected. Results: In the univariable Cox analysis, pre- (<i>p</i> = 0.689) and post-radiotherapy (RT) sarcopenia (<i>p</i> = 0.669) were not associated with OS. However, excessive muscle loss had a significant association with OS in both the univariable and multivariable analyses (all <i>p</i> = 0.001). Excessive muscle loss was also related to RFS in both the univariable (<i>p</i> = 0.011) and multivariable (<i>p</i> = 0.022) Cox analysis. Patients with excessive muscle loss had significantly lower levels of post-RT albumin (<i>p</i> < 0.001) and PNI (<i>p</i> < 0.001), higher levels of post-RT NLR (<i>p</i> = 0.031) and PLR (<i>p</i> = 0.071), larger decrease in albumin (<i>p</i> < 0.001) and PNI (<i>p</i> < 0.001) after NACRT, and larger increase in NLR (<i>p</i> = 0.051) and PLR (<i>p</i> = 0.088) after NACRT than in those with non-excessive muscle loss. Conclusion: Excessive muscle loss rather than pre- and post-RT sarcopenia was a significant prognostic factor for OS and RFS, and it was also related to nutritional and inflammatory markers.
topic esophageal cancer
neoadjuvant chemoradiotherapy
sarcopenia
skeletal muscle loss
nutrition
inflammation
url https://www.mdpi.com/2072-6694/12/4/925
work_keys_str_mv AT hangyulyoon prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT dongryuloh prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT yongchanahn prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT jaemyoungnoh prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT hongryullpyo prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT wonkyungcho prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT yunmisong prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT minsupark prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT nayounghwang prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT jongmusun prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT hongkwankim prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT jaeillzo prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT youngmogshim prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
_version_ 1724857855031377920
spelling doaj-490f53dd6d7d440dbfb70cbefc7071fb2020-11-25T02:23:41ZengMDPI AGCancers2072-66942020-04-011292592510.3390/cancers12040925Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal CancerHan Gyul Yoon0Dongryul Oh1Yong Chan Ahn2Jae Myoung Noh3Hongryull Pyo4Won Kyung Cho5Yun Mi Song6Minsu Park7Na Young Hwang8Jong-Mu Sun9Hong Kwan Kim10Jae Ill Zo11Young Mog Shim12Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Statistics, Keimyung University, Daegu 42601, KoreaStatistics and Data Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaBackgrounds: The relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) of esophageal cancer patients. Methods: We retrospectively collected the medical records of 248 male patients diagnosed with squamous cell esophageal cancer and who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgery. We measured the cross-sectional area of the skeletal muscle at the L3 vertebra level using computed tomography images and calculated the skeletal muscle index (SMI). Sarcopenia was defined as SMI <52.4 cm<sup>2</sup>/m<sup>2</sup>, and excessive muscle loss was defined as SMI change <−10.0%/50 days during NACRT. Moreover, laboratory test results, such as albumin, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) before and after NACRT, were collected. Results: In the univariable Cox analysis, pre- (<i>p</i> = 0.689) and post-radiotherapy (RT) sarcopenia (<i>p</i> = 0.669) were not associated with OS. However, excessive muscle loss had a significant association with OS in both the univariable and multivariable analyses (all <i>p</i> = 0.001). Excessive muscle loss was also related to RFS in both the univariable (<i>p</i> = 0.011) and multivariable (<i>p</i> = 0.022) Cox analysis. Patients with excessive muscle loss had significantly lower levels of post-RT albumin (<i>p</i> < 0.001) and PNI (<i>p</i> < 0.001), higher levels of post-RT NLR (<i>p</i> = 0.031) and PLR (<i>p</i> = 0.071), larger decrease in albumin (<i>p</i> < 0.001) and PNI (<i>p</i> < 0.001) after NACRT, and larger increase in NLR (<i>p</i> = 0.051) and PLR (<i>p</i> = 0.088) after NACRT than in those with non-excessive muscle loss. Conclusion: Excessive muscle loss rather than pre- and post-RT sarcopenia was a significant prognostic factor for OS and RFS, and it was also related to nutritional and inflammatory markers.https://www.mdpi.com/2072-6694/12/4/925esophageal cancerneoadjuvant chemoradiotherapysarcopeniaskeletal muscle lossnutritioninflammation